Africa Pharmaceuticals Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (Africa)

Description

The Africa pharmaceuticals market continues its remarkable growth trajectory, generating a staggering US$ 51 billion in revenue in 2024. A recent study by Fairfield Market Research forecasts a robust CAGR of 8.3%, positioning the market to reach a valuation of US$ 100 billion by the end of 2031. This upward trajectory is underpinned by several key factors shaping the industry's evolution.

Urbanization and Changing Lifestyles Fuel Healthcare Demand

Africa is currently witnessing rapid urbanization, with a significant portion of its population migrating from rural areas to urban centers. This shift is driven by increased employment opportunities, improved infrastructure, and enhanced access to services. As urbanization progresses, healthcare needs and demands are undergoing transformation.

Urbanization often accompanies lifestyle changes, including dietary shifts towards processed foods, reduced physical activity levels, and increased tobacco and alcohol consumption. These shifts contribute to the growing burden of non-communicable diseases (NCDs) in Africa, such as cardiovascular diseases, diabetes, cancer, and respiratory illnesses. Consequently, there is a rising demand for pharmaceutical products to manage and combat these chronic conditions.

African Continental Free Trade Area (AfCFTA) Sparks Market Transformation

The African Continental Free Trade Area (AfCFTA) presents a significant opportunity to address the challenge of fragmented markets that have historically hindered the competitiveness of African countries compared to Asian manufacturers. By establishing a continental market, AfCFTA enables economies of scale, encouraging higher production volumes and cost savings. This regional integration also fosters specialization, promoting the development of attractive regional procurement markets for investors.

Government Initiatives Drive Pharmaceutical Growth

Government initiatives play a pivotal role in driving the African pharmaceutical market. The AfCFTA-Anchored Pharmaceutical Initiative, for instance, aims to harmonize national standards and pool procurement efforts. This initiative seeks to attract increased investment in pharmaceutical production and exports, promoting self-sufficiency and economic growth.

Hurdles Faced by the African Pharmaceuticals Market

Despite these promising prospects, the African pharmaceutical market faces significant challenges. A notable obstacle is the lack of sustainable health financing mechanisms, which hinder access to affordable medicines. While African leaders committed to dedicating a minimum of 15% of the overall government budget to healthcare in the 2001 Abuja Declaration, only a handful of nations have met this objective. This shortfall results in high out-of-pocket payments, pushing many families below the poverty line.

Additionally, low health insurance coverage exacerbates the problem, leaving a large portion of the population unable to afford essential medicines. The overpriced medications make it difficult for individuals with low incomes to access necessary care, perpetuating the cycle of poverty.

Country-Wise Insights

Nigeria: A Lucrative Market for Pharmaceutical Manufacturers

Nigeria is emerging as a lucrative market for pharmaceutical manufacturers due to increasing investments in healthcare research and development. The government's initiatives to enhance healthcare access and affordability include programs to increase the availability of essential medicines and promote local manufacturing of pharmaceutical products.

Democratic Republic of Congo: Growing Emphasis on Local Manufacturing

The Democratic Republic of Congo is focusing on local production and manufacturing of pharmaceutical products, reducing dependency on imports. The rising population and increasing healthcare needs are driving the demand for medicines, vaccines, and other pharmaceutical products, making it a prominent market for industry players.

Competitive Landscape

The pharmaceutical sector in Africa is highly fragmented, with numerous regional players. Leading pharmaceutical and biotech companies are investing in research and development to introduce new drugs to the African market. Key players also consider pricing strategies aligned with local market dynamics and reimbursement systems, fostering market growth through collaborations and long-term contracts with other pharmaceutical manufacturers.

Key Companies Covered:

Sanofi S.A.
Pfizer Inc.
GSK Plc.
Novartis AG
Bayer AG
F.Hoffmann-La Roche Ltd.
AstraZeneca
Novo Nordisk A/S
Hikma Pharmaceuticals PLC
Merck & Co., Inc.
Bristol Myers Squibb Co.
Takeda Pharmaceutical Company Limited
Aspen Holdings
Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
May & Baker Nigeria PLC
Chemiron International Limited
Mopson Pharmaceutical Ltd.
Neimeth International Pharmaceuticals PLC
Pharma Deko PLC
Emzor Pharmaceutical Industries Limited
Swiss Pharma Nigeria Limited

Key Segments of Africa Pharmaceuticals Industry Research

Dosage Form:

Oral Formulations
- Tablets
- Capsules
- Powders & Granules
- Lozenges & Pastilles
- Gummies
- Others

Parenteral Formulations
- Solutions
- Suspensions
- Emulsions for Injection or Infusion
- Powder for Injection or Infusion
- Gel for Injection Implants

Topical Formulations
- Pastes
- Ointments & Oils
- Creams, Lotions, and Foams
- Gels, Tinctures, and Powder
- Sprays & Patches

Inhalation Formulations
- Pressurized Metered Dose Inhalers
- Dry Powder Inhalers (DPIs)
- Nebulizers

Country:

Nigeria
Benin
Democratic Republic of Congo
Republic of the Congo
Ivory Coast
Sierra Leone
Rwanda
Rest of Africa

1. Executive Summary

1.1. Africa Pharmaceuticals Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Africa Pharmaceuticals Market Outlook, 2018 - 2031

3.1. Africa Pharmaceuticals Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Oral Formulations
    - 3.1.1.1.1. Tablets
    - 3.1.1.1.2. Capsules
    - 3.1.1.1.3. Powders & Granules
    - 3.1.1.1.4. Lozenges & Pastilles
    - 3.1.1.1.5. Gummies
    - 3.1.1.1.6. Others
  - 3.1.1.2. Parenteral Formulations
    - 3.1.1.2.1. Solutions
    - 3.1.1.2.2. Suspensions
    - 3.1.1.2.3. Emulsions for Injection or Infusion
    - 3.1.1.2.4. Powder for Injection or Infusion
    - 3.1.1.2.5. Gel for Injection Implants
  - 3.1.1.3. Topical Formulations
    - 3.1.1.3.1. Pastes
    - 3.1.1.3.2. Ointments & Oils
    - 3.1.1.3.3. Creams, Lotions, and Foams
    - 3.1.1.3.4. Gels, Tinctures, and Powder
    - 3.1.1.3.5. Sprays & Patches
  - 3.1.1.4. Inhalation Formulations
  - 3.1.1.5. Pressurized Metered Dose Inhalers
  - 3.1.1.6. Dry Powder Inhalers (DPIs)
  - 3.1.1.7. Nebulizers
3.2. Africa Pharmaceuticals Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Nigeria
  - 3.2.1.2. Benin
  - 3.2.1.3. Democratic Republic of Congo
  - 3.2.1.4. Republic of the Congo
  - 3.2.1.5. Ivory Coast
  - 3.2.1.6. Sierra Leone
  - 3.2.1.7. Rwanda
  - 3.2.1.8. Rest of Africa

4. Nigeria Pharmaceuticals Market Outlook, 2018 - 2031

4.1. Nigeria Pharmaceuticals Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Oral Formulations
    - 4.1.1.1.1. Tablets
    - 4.1.1.1.2. Capsules
    - 4.1.1.1.3. Powders & Granules
    - 4.1.1.1.4. Lozenges & Pastilles
    - 4.1.1.1.5. Gummies
    - 4.1.1.1.6. Others
  - 4.1.1.2. Parenteral Formulations
    - 4.1.1.2.1. Solutions
    - 4.1.1.2.2. Suspensions
    - 4.1.1.2.3. Emulsions for Injection or Infusion
    - 4.1.1.2.4. Powder for Injection or Infusion
    - 4.1.1.2.5. Gel for Injection Implants
  - 4.1.1.3. Topical Formulations
    - 4.1.1.3.1. Pastes
    - 4.1.1.3.2. Ointments & Oils
    - 4.1.1.3.3. Creams, Lotions, and Foams
    - 4.1.1.3.4. Gels, Tinctures, and Powder
    - 4.1.1.3.5. Sprays & Patches
  - 4.1.1.4. Inhalation Formulations
  - 4.1.1.5. Pressurized Metered Dose Inhalers
  - 4.1.1.6. Dry Powder Inhalers (DPIs)
  - 4.1.1.7. Nebulizers
- 4.1.2. BPS Analysis/Market Attractiveness Analysis

5. Benin Pharmaceuticals Market Outlook, 2018 - 2031

5.1. Benin Pharmaceuticals Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Oral Formulations
    - 5.1.1.1.1. Tablets
    - 5.1.1.1.2. Capsules
    - 5.1.1.1.3. Powders & Granules
    - 5.1.1.1.4. Lozenges & Pastilles
    - 5.1.1.1.5. Gummies
    - 5.1.1.1.6. Others
  - 5.1.1.2. Parenteral Formulations
    - 5.1.1.2.1. Solutions
    - 5.1.1.2.2. Suspensions
    - 5.1.1.2.3. Emulsions for Injection or Infusion
    - 5.1.1.2.4. Powder for Injection or Infusion
    - 5.1.1.2.5. Gel for Injection Implants
  - 5.1.1.3. Topical Formulations
    - 5.1.1.3.1. Pastes
    - 5.1.1.3.2. Ointments & Oils
    - 5.1.1.3.3. Creams, Lotions, and Foams
    - 5.1.1.3.4. Gels, Tinctures, and Powder
    - 5.1.1.3.5. Sprays & Patches
  - 5.1.1.4. Inhalation Formulations
  - 5.1.1.5. Pressurized Metered Dose Inhalers
  - 5.1.1.6. Dry Powder Inhalers (DPIs)
  - 5.1.1.7. Nebulizers
- 5.1.2. BPS Analysis/Market Attractiveness Analysis

6. Democratic Republic of Congo Pharmaceuticals Market Outlook, 2018 - 2031

6.1. Democratic Republic of Congo Pharmaceuticals Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Oral Formulations
    - 6.1.1.1.1. Tablets
    - 6.1.1.1.2. Capsules
    - 6.1.1.1.3. Powders & Granules
    - 6.1.1.1.4. Lozenges & Pastilles
    - 6.1.1.1.5. Gummies
    - 6.1.1.1.6. Others
  - 6.1.1.2. Parenteral Formulations
    - 6.1.1.2.1. Solutions
    - 6.1.1.2.2. Suspensions
    - 6.1.1.2.3. Emulsions for Injection or Infusion
    - 6.1.1.2.4. Powder for Injection or Infusion
    - 6.1.1.2.5. Gel for Injection Implants
  - 6.1.1.3. Topical Formulations
    - 6.1.1.3.1. Pastes
    - 6.1.1.3.2. Ointments & Oils
    - 6.1.1.3.3. Creams, Lotions, and Foams
    - 6.1.1.3.4. Gels, Tinctures, and Powder
    - 6.1.1.3.5. Sprays & Patches
  - 6.1.1.4. Inhalation Formulations
  - 6.1.1.5. Pressurized Metered Dose Inhalers
  - 6.1.1.6. Dry Powder Inhalers (DPIs)
  - 6.1.1.7. Nebulizers
- 6.1.2. BPS Analysis/Market Attractiveness Analysis

7. Republic of the Congo Pharmaceuticals Market Outlook, 2018 - 2031

7.1. Republic of the Congo Pharmaceuticals Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Oral Formulations
    - 7.1.1.1.1. Tablets
    - 7.1.1.1.2. Capsules
    - 7.1.1.1.3. Powders & Granules
    - 7.1.1.1.4. Lozenges & Pastilles
    - 7.1.1.1.5. Gummies
    - 7.1.1.1.6. Others
  - 7.1.1.2. Parenteral Formulations
    - 7.1.1.2.1. Solutions
    - 7.1.1.2.2. Suspensions
    - 7.1.1.2.3. Emulsions for Injection or Infusion
    - 7.1.1.2.4. Powder for Injection or Infusion
    - 7.1.1.2.5. Gel for Injection Implants
  - 7.1.1.3. Topical Formulations
    - 7.1.1.3.1. Pastes
    - 7.1.1.3.2. Ointments & Oils
    - 7.1.1.3.3. Creams, Lotions, and Foams
    - 7.1.1.3.4. Gels, Tinctures, and Powder
    - 7.1.1.3.5. Sprays & Patches
  - 7.1.1.4. Inhalation Formulations
  - 7.1.1.5. Pressurized Metered Dose Inhalers
  - 7.1.1.6. Dry Powder Inhalers (DPIs)
  - 7.1.1.7. Nebulizers
- 7.1.2. BPS Analysis/Market Attractiveness Analysis

8. Ivory Coast Pharmaceuticals Market Outlook, 2018 - 2031

8.1. Ivory Coast Pharmaceuticals Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Oral Formulations
    - 8.1.1.1.1. Tablets
    - 8.1.1.1.2. Capsules
    - 8.1.1.1.3. Powders & Granules
    - 8.1.1.1.4. Lozenges & Pastilles
    - 8.1.1.1.5. Gummies
    - 8.1.1.1.6. Others
  - 8.1.1.2. Parenteral Formulations
    - 8.1.1.2.1. Solutions
    - 8.1.1.2.2. Suspensions
    - 8.1.1.2.3. Emulsions for Injection or Infusion
    - 8.1.1.2.4. Powder for Injection or Infusion
    - 8.1.1.2.5. Gel for Injection Implants
  - 8.1.1.3. Topical Formulations
    - 8.1.1.3.1. Pastes
    - 8.1.1.3.2. Ointments & Oils
    - 8.1.1.3.3. Creams, Lotions, and Foams
    - 8.1.1.3.4. Gels, Tinctures, and Powder
    - 8.1.1.3.5. Sprays & Patches
  - 8.1.1.4. Inhalation Formulations
  - 8.1.1.5. Pressurized Metered Dose Inhalers
  - 8.1.1.6. Dry Powder Inhalers (DPIs)
  - 8.1.1.7. Nebulizers
- 8.1.2. BPS Analysis/Market Attractiveness Analysis

9. Sierra Leone Pharmaceuticals Market Outlook, 2018 - 2031

9.1. Sierra Leone Pharmaceuticals Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
- 9.1.1. Key Highlights
  - 9.1.1.1. Oral Formulations
    - 9.1.1.1.1. Tablets
    - 9.1.1.1.2. Capsules
    - 9.1.1.1.3. Powders & Granules
    - 9.1.1.1.4. Lozenges & Pastilles
    - 9.1.1.1.5. Gummies
    - 9.1.1.1.6. Others
  - 9.1.1.2. Parenteral Formulations
    - 9.1.1.2.1. Solutions
    - 9.1.1.2.2. Suspensions
    - 9.1.1.2.3. Emulsions for Injection or Infusion
    - 9.1.1.2.4. Powder for Injection or Infusion
    - 9.1.1.2.5. Gel for Injection Implants
  - 9.1.1.3. Topical Formulations
    - 9.1.1.3.1. Pastes
    - 9.1.1.3.2. Ointments & Oils
    - 9.1.1.3.3. Creams, Lotions, and Foams
    - 9.1.1.3.4. Gels, Tinctures, and Powder
    - 9.1.1.3.5. Sprays & Patches
  - 9.1.1.4. Inhalation Formulations
  - 9.1.1.5. Pressurized Metered Dose Inhalers
  - 9.1.1.6. Dry Powder Inhalers (DPIs)
  - 9.1.1.7. Nebulizers
- 9.1.2. BPS Analysis/Market Attractiveness Analysis

10. Rwanda Pharmaceuticals Market Outlook, 2018 - 2031

10.1. Rwanda Pharmaceuticals Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
- 10.1.1. Key Highlights
  - 10.1.1.1. Oral Formulations
    - 10.1.1.1.1. Tablets
    - 10.1.1.1.2. Capsules
    - 10.1.1.1.3. Powders & Granules
    - 10.1.1.1.4. Lozenges & Pastilles
    - 10.1.1.1.5. Gummies
    - 10.1.1.1.6. Others
  - 10.1.1.2. Parenteral Formulations
    - 10.1.1.2.1. Solutions
    - 10.1.1.2.2. Suspensions
    - 10.1.1.2.3. Emulsions for Injection or Infusion
    - 10.1.1.2.4. Powder for Injection or Infusion
    - 10.1.1.2.5. Gel for Injection Implants
  - 10.1.1.3. Topical Formulations
    - 10.1.1.3.1. Pastes
    - 10.1.1.3.2. Ointments & Oils
    - 10.1.1.3.3. Creams, Lotions, and Foams
    - 10.1.1.3.4. Gels, Tinctures, and Powder
    - 10.1.1.3.5. Sprays & Patches
  - 10.1.1.4. Inhalation Formulations
  - 10.1.1.5. Pressurized Metered Dose Inhalers
  - 10.1.1.6. Dry Powder Inhalers (DPIs)
  - 10.1.1.7. Nebulizers
- 10.1.2. BPS Analysis/Market Attractiveness Analysis

11. Rest of Africa Pharmaceuticals Market Outlook, 2018 - 2031

11.1. Rest of Africa Pharmaceuticals Market Outlook, by Dosage Form, Value (US$ Bn), 2018 - 2031
- 11.1.1. Key Highlights
  - 11.1.1.1. Oral Formulations
    - 11.1.1.1.1. Tablets
    - 11.1.1.1.2. Capsules
    - 11.1.1.1.3. Powders & Granules
    - 11.1.1.1.4. Lozenges & Pastilles
    - 11.1.1.1.5. Gummies
    - 11.1.1.1.6. Others
  - 11.1.1.2. Parenteral Formulations
    - 11.1.1.2.1. Solutions
    - 11.1.1.2.2. Suspensions
    - 11.1.1.2.3. Emulsions for Injection or Infusion
    - 11.1.1.2.4. Powder for Injection or Infusion
    - 11.1.1.2.5. Gel for Injection Implants
  - 11.1.1.3. Topical Formulations
    - 11.1.1.3.1. Pastes
    - 11.1.1.3.2. Ointments & Oils
    - 11.1.1.3.3. Creams, Lotions, and Foams
    - 11.1.1.3.4. Gels, Tinctures, and Powder
    - 11.1.1.3.5. Sprays & Patches
  - 11.1.1.4. Inhalation Formulations
  - 11.1.1.5. Pressurized Metered Dose Inhalers
  - 11.1.1.6. Dry Powder Inhalers (DPIs)
  - 11.1.1.7. Nebulizers
- 11.1.2. BPS Analysis/Market Attractiveness Analysis

12. Competitive Landscape

12.1. Company Market Share Analysis, 2023
12.2. Competitive Dashboard
12.3. Company Profiles
- 12.3.1. Sanofi S.A.
  - 12.3.1.1. Company Overview
  - 12.3.1.2. Product Portfolio
  - 12.3.1.3. Financial Overview
  - 12.3.1.4. Business Strategies and Development
- 12.3.2. Pfizer Inc.
  - 12.3.2.1. Company Overview
  - 12.3.2.2. Product Portfolio
  - 12.3.2.3. Financial Overview
  - 12.3.2.4. Business Strategies and Development
- 12.3.3. GSK Plc.
  - 12.3.3.1. Company Overview
  - 12.3.3.2. Product Portfolio
  - 12.3.3.3. Financial Overview
  - 12.3.3.4. Business Strategies and Development
- 12.3.4. Novartis AG
  - 12.3.4.1. Company Overview
  - 12.3.4.2. Product Portfolio
  - 12.3.4.3. Financial Overview
  - 12.3.4.4. Business Strategies and Development
- 12.3.5. Bayer AG
  - 12.3.5.1. Company Overview
  - 12.3.5.2. Product Portfolio
  - 12.3.5.3. Financial Overview
  - 12.3.5.4. Business Strategies and Development
- 12.3.6. F.Hoffmann-La Roche Ltd.
  - 12.3.6.1. Company Overview
  - 12.3.6.2. Product Portfolio
  - 12.3.6.3. Financial Overview
  - 12.3.6.4. Business Strategies and Development
- 12.3.7. AstraZeneca
  - 12.3.7.1. Company Overview
  - 12.3.7.2. Product Portfolio
  - 12.3.7.3. Financial Overview
  - 12.3.7.4. Business Strategies and Development
- 12.3.8. Novo Nordisk A/S
  - 12.3.8.1. Company Overview
  - 12.3.8.2. Product Portfolio
  - 12.3.8.3. Financial Overview
  - 12.3.8.4. Business Strategies and Development
- 12.3.9. Hikma Pharmaceuticals PLC
  - 12.3.9.1. Company Overview
  - 12.3.9.2. Product Portfolio
  - 12.3.9.3. Financial Overview
  - 12.3.9.4. Business Strategies and Development
- 12.3.10. Merck & Co., Inc.
  - 12.3.10.1. Company Overview
  - 12.3.10.2. Product Portfolio
  - 12.3.10.3. Financial Overview
  - 12.3.10.4. Business Strategies and Development
- 12.3.11. Bristol Myers Squibb Co.
  - 12.3.11.1. Company Overview
  - 12.3.11.2. Product Portfolio
  - 12.3.11.3. Financial Overview
  - 12.3.11.4. Business Strategies and Development
- 12.3.12. Takeda Pharmaceutical Company Limited
  - 12.3.12.1. Company Overview
  - 12.3.12.2. Product Portfolio
  - 12.3.12.3. Financial Overview
  - 12.3.12.4. Business Strategies and Development
- 12.3.13. Aspen Holdings
  - 12.3.13.1. Company Overview
  - 12.3.13.2. Product Portfolio
  - 12.3.13.3. Financial Overview
  - 12.3.13.4. Business Strategies and Development

13. Appendix

13.1. Research Methodology
13.2. Report Assumptions
13.3. Acronyms and Abbreviations